Setup, so nobody has to ask: a 27G needle · 5 mg/mL.
The units are where I keep going wrong, so please be explicit about them.
I have sanity-checked the order of magnitude and it seems right, which is not the same as being right.
Is my approach right even if my number is wrong?
At 5 mg/mL every microlitre left behind is 5 µg, so a 50 µL hub costs 0.25 mg per draw and a 5 µL fixed-needle barrel costs 0.025 mg. Multiply by the draws, not by the doses: ten draws through a 50 µL dead space is 2.5 mg gone, which at 5 mg/mL is 0.5 mL of solution you paid for and never administered. Against a 2 mg dose that 50 µL is 12.5 per cent; against a 0.25 mg dose it is 100 per cent, which is why the loss matters most at exactly the doses where you can least afford it. a 27G needle has a bore, a hub and a length, and the hub dominates: a fixed-needle insulin barrel has almost none, a luer connection has a measurable one before the needle even starts.
The distinction that resolves most of these questions is understanding that dead space is a fixed volume — typically 3 to 5 µL in a fixed-needle syringe and 35 to 100 µL in a luer-lock — and its cost scales with how small your draws are.
At 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.
| Configuration | Dead volume | Loss at 5 mg/mL | Over 20 draws |
|---|---|---|---|
| Fixed-needle insulin syringe | 3–5 µL | 15–25 µg | 0.3–0.5 mg |
| Low-dead-space, detachable | <2 µL | <10 µg | <0.2 mg |
| Standard luer-lock + 30G | 35–60 µL | 175–300 µg | 3.5–6 mg |
| Luer-lock + 21G drawing needle | 70–100 µL | 350–500 µg | 7–10 mg |
Concretely, delivered peptide = 10 x 0.5 mg = 5.0 mg. Lost to dead space = 10 x 84 µL = 840 µL x 0.005 = 4.2 mg. Yield = 50 per cent.
The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.
The limitation is that even with perfect technique, some loss is irreducible unless you switch to a low-dead-space syringe.
If cost matters, this is the first thing to change, not the last.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsA fixed-needle insulin syringe holds roughly 3 to 5 µL dead space and costs the same as a luer-lock syringe with 35 to 100 µL dead space.
Configuration B — 0.5 mL fixed-needle U-100 insulin syringe, dead space 2 µL: volume removed per draw = 100 + 2 = 102 µL.
Stated carefully, draws available = 2000 / 102 = 19.6, so 19 full draws. Delivered peptide = 19 x 0.5 mg = 9.5 mg. Lost to dead space = 19 x 2 µL = 38 µL x 0.005 = 0.19 mg. Yield = 95 per cent.
The caveat is that dead space is a yield loss and not a dose-accuracy loss, so the person feeling this loss most is the person with the most total draws.
Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.
edited 26 Aug 2024 by ivo_paunovic — updated for the 2026 guidance change
To be exact about it, the switch to a low-dead-space syringe nearly doubles your usable vial, which is better than switching suppliers if you are looking for cost savings.
Dead space quantified: a fixed-needle insulin syringe holds roughly 3 to 5 µL in the hub and needle after the plunger bottoms out. A luer-lock syringe with a detachable needle holds 35 to 100 µL depending on the hub design.
Corollary that follows immediately: changing needle gauge or length barely changes your losses.
Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.
One qualification: the dead space does not affect the dose accuracy if the hub was full of solution at the start of the draw.
The switch nearly doubles your vial, which is better than most other optimisations combined.
Before anything else: understand that dead space is a property of the syringe architecture, not of the needle gauge.
Low-dead-space syringe designs either have the needle bonded directly to the barrel — a fixed-needle syringe, which is the cheapest route — or add a moulded projection on the plunger tip that fills the luer cone.
Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.
Write the arithmetic on the vial label. It costs nothing and it removes the step where you reconstruct it from memory at an inconvenient moment.
Start from the worked arithmetic: a 10 mg vial reconstituted with 2 mL gives 5 mg/mL. One hundred microliter draws are 0.5 mg each. At 84 µL dead space per draw, half your vial disappears into the hub.
The complete rule: fix the syringe architecture first, and then the reconstitution volume becomes a free choice you can make on stability grounds rather than on economics.
The general principle here — that peptides adsorb and denature at air–liquid and solid–liquid interfaces — is standard formulation science, and it is why licensed presentations contain a surfactant such as polysorbate 20 or 80. A research vial does not, which is precisely why handling matters more, not less.
The practical summary: fine gauge, gentle swirl, diluent down the wall, room temperature before drawing, and check the syringe scale against the barrel rather than against your assumption.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.